SUPN logo

Supernus Pharmaceuticals, Inc.

SUPN

SUPN: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

more

Show SUPN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of SUPN by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec. 23, 2022
Gilbert Cisneros House / D Purchase $1,001 - $15,000 Nov. 13, 2020
Gilbert Cisneros House / D Purchase $1,001 - $15,000 Jul. 17, 2020
Gilbert Cisneros House / D Purchase $1,001 - $15,000 Jun. 01, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 May. 28, 2020
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by SUPN's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $20,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Apr 17, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Feb 07, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 19, 2022 Issue: Medicare/Medicaid Health Issues
U.S. Patents

New patents grants

  • Patent Title: Method of treatment of aggression May. 02, 2023
  • Patent Title: Derivatives of substituted morpholines and uses thereof Apr. 25, 2023
  • Patent Title: Method of treatment of attention deficit/hyperactivity disorder (adhd) Oct. 04, 2022
  • Patent Title: Use of higher doses of modified release huperzine formulations Jun. 07, 2022
  • Patent Title: Method of treatment of attention deficit/hyperactivity disorder (adhd) May. 10, 2022
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Nov. 09, 2021
  • Patent Title: Methods of producing molindone and its salts Sep. 14, 2021
  • Patent Title: Stabilized formulations of cns compounds Aug. 03, 2021
  • Patent Title: Methods of producing molindone and its salts Jun. 09, 2020
  • Patent Title: Sustained-release formulations of topiramate Jun. 11, 2019
  • Patent Title: Formulations of viloxazine Apr. 23, 2019
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Mar. 05, 2019
  • Patent Title: Method of treatment of aggression Feb. 12, 2019
  • Patent Title: Methods for producing viloxazine salts and novel polymorphs thereof Dec. 25, 2018
  • Patent Title: Stabilized formulations of cns compounds Dec. 11, 2018
  • Patent Title: Methods of producing molindone and its salts Sep. 25, 2018
  • Patent Title: Method of treatment of aggression Aug. 28, 2018
  • Patent Title: Methods for producing viloxazine salts and novel polymorphs thereof Jun. 26, 2018
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jan. 02, 2018
  • Patent Title: Methods of producing molindone and its salts Oct. 31, 2017
  • Patent Title: Method of treatment of aggression Oct. 31, 2017
  • Patent Title: Topiramate compositions and methods of enhancing its bioavailability Aug. 29, 2017
  • Patent Title: Formulations of viloxazine May. 30, 2017
  • Patent Title: Sustained-release formulations of topiramate Apr. 18, 2017
  • Patent Title: Formulations of viloxazine Mar. 28, 2017
  • Patent Title: Osmotic drug delivery system Feb. 14, 2017
  • Patent Title: Methods of producing molindone and its salts Feb. 07, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 31, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 24, 2017
  • Patent Title: Viloxazine compositions Sep. 06, 2016
  • Patent Title: Methods for producing viloxazine salts and novel polymorphs thereof Aug. 02, 2016
  • Patent Title: Osmotic drug delivery system Jul. 19, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jun. 21, 2016
  • Patent Title: Formulations of viloxazine Jun. 07, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof May. 31, 2016
  • Patent Title: Less abusable pharmaceutical preparations Apr. 12, 2016
  • Patent Title: Drug formulations having reduced abuse potential Sep. 29, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Sustained-release formulations of topiramate Mar. 31, 2015
  • Patent Title: Methods of producing molindone and its salts Feb. 17, 2015
  • Patent Title: Drug formulations having reduced abuse potential Dec. 09, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 18, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 04, 2014
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 02, 2014
  • Patent Title: Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics Aug. 19, 2014
  • Patent Title: Stabilized formulations of cns compounds Jun. 10, 2014
  • Patent Title: Osmotic drug delivery system Jun. 10, 2014
  • Patent Title: Once daily formulations of tetracyclines Apr. 29, 2014
  • Patent Title: Compositions of quaternary ammonium compounds containing bioavailability enhancers Apr. 29, 2014
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of SUPN in WallStreetBets Daily Discussion

SUPN News

Recent insights relating to SUPN

CNBC Recommendations

Recent picks made for SUPN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SUPN

Corporate Flights

Flights by private jets registered to SUPN